ArticleJournal of translational medicine2025
Mucoadhesive polydopamine-coated nanoparticle-mediated inner ear drug delivery for hearing loss treatment.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Enhancing the therapeutic efficacy of dexamethasone for oral ulcers through adhesive gelatin hydrogel-based nano-delivery system.Materials today. Bio · 2026Article
- Multimodal Magnetic, Photothermal, Ultrasonic, and Vibrational Actuation of Drug-Loaded Superparamagnetic Iron Oxide Nanoparticles for Enhanced Transport Across Semipermeable Membranes.Bioengineering (Basel, Switzerland) · 2026Article
- Targeting ferroptosis in sensorineural hearing loss: mechanisms, therapeutics, and translational prospects.Frontiers in neurologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
This study investigated the potential of mucoadhesive polymeric nanoparticles coated with polydopamine (Dopa-NPs) for inner ear drug delivery. Dopa, inspired by mussel adhesion proteins, leveraged the mucoadhesive properties of NPs and enhanced their retention within the cochlea. Dopa-NPs were compared with non-adhesive uncoated control NPs to reveal their safety and drug delivery efficiency. The safety evaluation demonstrated no toxicity during in vitro test using HEI-OC1 cells and in vivo test using mouse with auditory function assessment. When coumarin-encapsulated NPs were administered through intratympanic injection to mice, Dopa-NPs provided intense fluorescence in the inner ear compared to non-adhesive control NPs. Furthermore, dexamethasone (Dex)-encapsulated Dopa-NPs exhibited significantly higher drug concentrations in the cochlea than dexamethasone sodium phosphate and uncoated NPs. Finally, in vivo test using an ototoxicity-induced animal model showed that Dopa-NPs improved hearing protection, as indicated by the auditory brainstem response (ABR) test. In conclusion, mucoadhesive Dopa-NPs exhibit enhanced drug delivery efficiency and safety, offering a promising strategy for inner ear drug delivery and chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.